Robert J. Bitterman, Director at RXi Pharmaceuticals Corp (RXII), bought 1,000 shares at $4.13 ($4K) on 2013-08-05, disclosed to the SEC on 2013-08-05.
Open-market purchase of $4k RXII by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.01 | 100 | $401 | 9.8% |
| 2 | $4.02 | 100 | $402 | 9.8% |
| 3 | $4.05 | 100 | $405 | 9.9% |
| 4 | $4.05 | 200 | $810 | 19.8% |
| 5 | $4.13 | 500 | $2K | 50.6% |
| Total | $4.08 avg | 1,000 |
| $4K |
| 100% |
| Filing → |
| PHIO | BUY | 2026-01-02 | $5K | — | Filing → |
| PHIO | BUY | 2025-12-29 | $5K | — | Filing → |
| PHIO | BUY | 2025-11-24 | $6K | — | Filing → |